Intravenous (IV) Ibuprofen Market – Know Latest Trends & Forecast for Long-Term Business Planning By 2027

UPDATE AVAILABLE ON-DEMAND

The global Intravenous (IV) Ibuprofen market is expected to garner $14.2 million by 2022, registering a CAGR of 20.0% during the period 2016-2022. The pain indication segment accounted for over three-fourths share in 2015 and is expected to maintain its dominance throughout the forecast period.

The major factors that boost the market growth include, increase in adoption of an intravenous mode of drug delivery for acute pain management due to faster onset of action as compared to the other routes (oral and transdermal mode of administration) and targeted drug delivery property.

Download Free Report Sample @ https://www.alliedmarketresearch.com/request-sample/1387

The market growth is further augmented as IV ibuprofen improves pain management with less dependence on opioid analgesic medication, which may lead to several health complications such as sedation, dizziness, and others. Caldolor (Cumberland Pharmaceuticals) is the only injectable ibuprofen drug available in the market; hence, it has huge demand with minimal competition. However, numerous factors are likely to restrain the market growth such as lengthy approval process and limited geographic (country specific) approvals.

The U.S. is anticipated to remain the highest revenue-generating region during the forecast period, owing to the widespread adoption of IV Ibuprofen for treating pain and fever. However, Australia is expected to grow rapidly during the forecast period, owing to recent entry of IV Ibuprofen in this market, increasing awareness of non-steroidal anti-inflammatory drugs, and shifting trend towards intravenous mode of drug delivery.

The IV Ibuprofen market is dominated by Cumberland Pharmaceuticals and is actively engaged in research for the development of novel IV Ibuprofen products

Inquire before buying @ https://www.alliedmarketresearch.com/purchase-enquiry/1387

The Major Key Players Are:

• Cumberland Pharmaceuticals Inc.
• Alveda Pharmaceuticals, Inc.
• (Acquired by Teligent, Inc.)
• CSL Limited
• Sandor Medicaids Pvt. Ltd.
• PT. Soho Industri Pharmasi
• Germin MED
• Grifols S.A.
• Harbin Gloria Pharmaceuticals Co., Ltd.
• Al Nabeel International Ltd.
• Laboratorios Valmorca, C.A.

Key Findings of IV Ibuprofen Market:

• Fever is projected to be the fastest growing indication segment.
• Australia IV Ibuprofen market is expected to grow at the fastest CAGR of 14.7% from 2015 to 2020.
• In 2015, the U.S. and Canada collectively accounted for more than three-fourths of the global IV Ibuprofen market.

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

About Us:

Allied Market Research (AMR) is a full-service market research and business -consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

This release was published on openPR.